These data indicate that, because Tr1-treated CIA mice exhibit increased IFN-γ production in vivo, co-infusion of MSCs and Tr1 cells may induce an increase in IDO production in IFN-γ-licensed MSCs, and may therefore be applicable as a treatment for RA in a synergistic manner. The gene discussed is IFNG; the disease is rheumatoid arthritis.